Brought to you by 
Concert licenses deuterium-modified narcolepsy program to Jazz
05 Feb 2014
Executive Summary
Concert Pharmaceuticals Inc. (chemically modified versions of existing small molecules) has licensed oncology and CNS company Jazz Pharmaceuticals PLC exclusive global rights to its deuterium-containing sodium oxybate analog (D-SXB) program. The deal includes lead preclinical candidate C10323, which could be ready for IND filing in late 2013.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Concert licenses deuterium-modified narcolepsy program to Jazz
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice